Newborn Screening with (C16 + C18:1)/C2 and C14/C3 for Carnitine Palmitoyltransferase II Deficiency throughout Japan Has Revealed C12/C0 as an Index of Higher Sensitivity and Specificity

Carnitine palmitoyltransferase (CPT) II deficiency is a long-chain fatty acid oxidation disorder. It manifests as (1) a lethal neonatal form, (2) a hypoglycemic form, or (3) a myopathic form. The second form can cause sudden infant death and is more common among Japanese people than in other ethnic groups. Our study group had earlier used (C16 + C18:1)/C2 to conduct a pilot newborn screening (NBS) study, and found that the use of C14/C3 for screening yielded lower rates of false positivity; in 2018, as a result, nationwide NBS for CPT II deficiency started. In this study, we evaluated the utility of these ratios in 71 NBS-positive infants and found that the levels of both C14/C3 and (C16 + C18:1)/C2 in patients overlapped greatly with those of infants without the disease. Among the levels of acylcarnitines with various chain lengths (C18 to C2) and levels of free carnitine (C0) as well as their ratios of various patterns, C12/C0 appeared to be a promising index that could reduce false-positive results without missing true-positive cases detected by current indices. Although some cases of the myopathic form may go undetected even with C12/C0, its use will help prevent life-threatening onset of the hypoglycemic form of CPT II deficiency.

[1]  Zhenzhen Hu,et al.  Newborn Screening for Mitochondrial Carnitine-Acylcarnitine Cycle Disorders in Zhejiang Province, China , 2022, Frontiers in Genetics.

[2]  T. Taketani,et al.  The frequencies of very long-chain acyl-CoA dehydrogenase deficiency genetic variants in Japan have changed since the implementation of expanded newborn screening. , 2022, Molecular genetics and metabolism.

[3]  B. Burton,et al.  Diagnosis and Clinical Management of Long-chain Fatty-acid Oxidation Disorders: A Review. , 2021, TouchREVIEWS in endocrinology.

[4]  S. Dyack,et al.  Detection of Early Onset Carnitine Palmitoyltransferase II Deficiency by Newborn Screening: Should CPT II Deficiency Be a Primary Disease Target? , 2021, International journal of neonatal screening.

[5]  J. Vockley,et al.  Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders , 2021, Genetics in Medicine.

[6]  Y. Shigematsu,et al.  Evaluation of Metabolic Defects in Fatty Acid Oxidation Using Peripheral Blood Mononuclear Cells Loaded with Deuterium-Labeled Fatty Acids , 2019, Disease markers.

[7]  K. Hara,et al.  Carnitine palmitoyltransferase II deficiency with a focus on newborn screening , 2018, Journal of Human Genetics.

[8]  O. Ohara,et al.  Newborn screening for carnitine palmitoyltransferase II deficiency using (C16+C18:1)/C2: Evaluation of additional indices for adequate sensitivity and lower false-positivity. , 2017, Molecular genetics and metabolism.

[9]  Jennifer A. Salant,et al.  Missed Newborn Screening Case of Carnitine Palmitoyltransferase-II Deficiency. , 2016, JIMD reports.

[10]  S. Zierz,et al.  Carnitine palmitoyltransferase II (CPT II) deficiency: Genotype–Phenotype analysis of 50 patients , 2014, Journal of the Neurological Sciences.

[11]  S. Okada,et al.  Acute severe encephalopathy related to human herpesvirus-6 infection in a patient with carnitine palmitoyltransferase 2 deficiency carrying thermolabile variants , 2013, Brain and Development.

[12]  D. Matern,et al.  Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting , 2010, Journal of Inherited Metabolic Disease.

[13]  A. Ohtake,et al.  Mutations of carnitine palmitoyltransferase II (CPT II) in Japanese patients with CPT II deficiency , 2008, Clinical genetics.

[14]  Y. Hasegawa,et al.  A survey of Japanese patients with mitochondrial fatty acid β-oxidation and related disorders as detected from 1985 to 2000 , 2002, Brain and Development.

[15]  J. Kira,et al.  Two CPT2 mutations in three Japanese patients with carnitine palmitoyltransferase II deficiency: Functional analysis and association with polymorphic haplotypes and two clinical phenotypes , 1998, Human mutation.